Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib

O. Fiala, M. Pesek, J. Finek, L. Benesova, M. Minarik, Z. Bortlicek, O. Topolcan,

. 2014 ; 34 (6) : 3205-3210.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074145

BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. RESULTS: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.

000      
00000naa a2200000 a 4500
001      
bmc14074145
003      
CZ-PrNML
005      
20170411121803.0
007      
ta
008      
141006s2014 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)24922695
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Fiala, Ondřej $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic fiala.o@centrum.cz. $7 xx0209889
245    10
$a Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib / $c O. Fiala, M. Pesek, J. Finek, L. Benesova, M. Minarik, Z. Bortlicek, O. Topolcan,
520    9_
$a BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. RESULTS: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.
650    _2
$a adenokarcinom $x krev $x farmakoterapie $x mortalita $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny nádorové $x krev $7 D000951
650    _2
$a karcinoembryonální antigen $x krev $7 D002272
650    _2
$a nemalobuněčný karcinom plic $x krev $x farmakoterapie $x mortalita $7 D002289
650    _2
$a spinocelulární karcinom $x krev $x farmakoterapie $x mortalita $7 D002294
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a keratin-19 $x krev $7 D053539
650    _2
$a nádory plic $x krev $x farmakoterapie $x mortalita $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a chinazoliny $x terapeutické užití $7 D011799
650    _2
$a erbB receptory $x antagonisté a inhibitory $x genetika $7 D066246
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
650    _2
$a nádorové biomarkery $x krev $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pesek, Milos $u Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic.
700    1_
$a Benesova, Lucie $u Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic.
700    1_
$a Minarik, Marek $u Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic.
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
700    1_
$a Topolcan, Ondrej $u Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 34, č. 6 (2014), s. 3205-3210
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24922695 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20170411122102 $b ABA008
999    __
$a ok $b bmc $g 1042028 $s 873057
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 34 $c 6 $d 3205-3210 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20141006
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace